1. Home
  2. Directory
  3. Massachusetts
  4. Brighton
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1982992145

DR. DIANA ROSE GREEN O.D.
Prescription History 1982992145
Optometrist in Brighton, MA

NPI Status: Active since July 21, 2011

Contact Information

11 NEVINS ST STE 205
BRIGHTON, MA
ZIP 02135
Phone: (617) 783-5050
Fax: (617) 783-0734

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. DIANA ROSE GREEN O.D., an active Optometrist specialist practicing in Brighton, MA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 111 documented patient claims. Among these therapy options, the most frequently utilized medication is Restasis, which accounts for 65 claims alone.

Medication Index

L
O
R
No matching medications currently found on file.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 33
30-Day Fills 65.7
Days Supply 1,954
MA State Average Benchmarks
Peer Average Claims181.0
Peer Average 30-Day Fills350.7
Peer Average Days Supply10,119
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.8% less volume than the regional standard for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $781.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.69

State Avg Cost Per Claim

$22.08

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Olopatadine Hcl

Generic Formulation: Olopatadine HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 413
MA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills26.4
Peer Average Days Supply696
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $711.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$54.69

State Avg Cost Per Claim

$53.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antihistamine used to treat itching and redness in the eyes due to allergies. This medication is not recommended for the treatment of eye irritation due to wearing contact lenses.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 65
30-Day Fills 111.0
Days Supply 3,330
MA State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills90.7
Peer Average Days Supply2,704
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $72,554.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,116.23

State Avg Cost Per Claim

$1,116.33

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. DIANA ROSE GREEN O.D. provides transparency into local medical care patterns within Brighton, MA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.